To use our website in an optimal way, please activate JavaScript in your Browser.

J Acquir Immune Defic Syndr, 2020; 84(1): 101-106, PMID: 32141960

Deficits in bone architecture and strength in children living with HIV on antiretroviral therapy.

Year: 2020

Shiau S, Yin MT, Strehlau R, Burke M, Patel F, Kuhn L, Coovadia A, Norris SA, Arpadi SM
Department of Biostatistics and Epidemiology, Rutgers School of Public Health, Piscataway, NJ, USA.


BACKGROUND: Reduced bone mineral mass by dual x-ray absorptiometry (DXA) is reported in children living with HIV (CLWH), but few studies of bone microarchitecture, particularly in sub-Saharan Africa, have been conducted. Here, we compare bone architecture and strength in black South African CLWH and uninfected control children by peripheral quantitative computed tomography (pQCT). SETTING: and Methods: 172 CLWH on antiretroviral therapy (ART) and 98 controls in the CHANGES Bone Study in Johannesburg, South Africa received pQCT scans of the radius and tibia. Measurements included trabecular and cortical volumetric BMD (vBMD) and bone strength, estimated by the polar strength strain index (SSI), a validated measure of fracture risk. RESULTS: CLWH (51% male) and controls (63% male) were an average of 10.4 years of age. Mean ART duration for CLWH was 9.5 years, with 70.9% on an efavirenz-based, 28.5% on a lopinavir/ritonavir-based, and 1 child on an atazanavir/ritonavir-based regimen. Male CLWH had lower trabecular vBMD at the radius than controls after adjustment for age, radial length, and Tanner stage (beta=-17.3, SE=7.2, p=0.018). Bone strength by polar SSI was lower in CLWH than controls (778 vs. 972 mm, p<0.01). CLWH on a LPV/r-based regimen had lower trabecular vBMD (199 vs. 222 mg/cm, p<0.001) and cortical vBMD (1074 vs. 1093 mg/cm, p=0.004) than those on an efavirenz-based regimen. No difference in bone strength by polar SSI was observed between treatment groups. CONCLUSION: CLWH initiated on ART early in life with well-controlled HIV have deficits in bone architecture and reductions in bone strength as detected by pQCT.

GID: 5070; Last update: 10.03.2020